COX-2、CCR7表达与大肠癌转移关系的研究
摘要
目的探讨COX-2、CCR7表达与大肠癌组织病理分化、浸润深度、淋巴转移等临床病理学参数的关系,并分析COX-2、CCR7表达的相关性。
方法采用免疫组织化学方法对大肠癌组织80例、大肠癌癌周组织40例石蜡包埋切片进行染色,检测COX-2、CCR7的表达,分析其在大肠癌组织的表达与临床病理学参数的关系,对COX-2、CCR7的表达进行相关性分析。
结果在大肠癌组织,COX-2、CCR7均高表达,表达率分别为72.5%和67.5%,二者表达呈正相关(P＜0.05)。COX-2、CCR7的表达均与肿瘤的浸润深度、TNM分期、淋巴转移、肿瘤大小相关(P＜0.05),与大肠癌患者的诊断年龄、性别等因素无关(P＞0.05)。CCR7的表达与肿瘤的病理分化、肿瘤部位相关,但COX-2的表达与此无关。
结论COX-2、CCR7在大肠癌组织高表达,二者表达呈正相关。COX-2、CCR7的表达与大肠癌的浸润深度、TNM分期、淋巴转移、肿瘤大小等临床病理学参数有关。
Objective This study was designed to evaluate the expression of COX-2 and CCR7 in human colorectal cancer and determine their relationships and correlations with lymph node metastasis,tumor differentiation,invasion depth,lymphatic metastasis and other clinicopathologic parameters.
Methods Tissue samples of primary tumors from 80 colorectal cancer patients and normal colorectal tissue adjacent to cancer from 40 colorectal cancer patients,undergoing paraffin imbedding slices were immunohistochemically examined for COX-2 and CCR7 expressions.
Results COX-2 and CCR7 were highly expressed in colorectal cancer tissues,the positive rate of COX-2 and CCR7 in the primary tumor was 72.5%and 67.5%,respectively.A significant correlation was found between the expression scores of COX-2 and CCR7(P＜0.05),and both also were correlated with several clinicopathologic parameters, including invasion depth,lymph node metastasis,TNM stage and primary tumor size(P＜0.05),but both were not related to patients'age, sex and other factors(P＞0.05).In addition,only CCR7 expression was associated with histology and tumor site(P＜0.05).
Conclusions High expression of COX-2 and CCR7 in human colorectal cancer was a significantly correlated.COX-2 and CCR7 were significantly associated with clinicopathologic parameters,including invasion depth,lymph node metastasis,TNM stage and primary tumor size.This indicates that detection of COX-2 and CCR7 will be helpful to predicting clincally the metastasis of colorectal cancer.
方法采用免疫组织化学方法对大肠癌组织80例、大肠癌癌周组织40例石蜡包埋切片进行染色,检测COX-2、CCR7的表达,分析其在大肠癌组织的表达与临床病理学参数的关系,对COX-2、CCR7的表达进行相关性分析。
结果在大肠癌组织,COX-2、CCR7均高表达,表达率分别为72.5%和67.5%,二者表达呈正相关(P＜0.05)。COX-2、CCR7的表达均与肿瘤的浸润深度、TNM分期、淋巴转移、肿瘤大小相关(P＜0.05),与大肠癌患者的诊断年龄、性别等因素无关(P＞0.05)。CCR7的表达与肿瘤的病理分化、肿瘤部位相关,但COX-2的表达与此无关。
结论COX-2、CCR7在大肠癌组织高表达,二者表达呈正相关。COX-2、CCR7的表达与大肠癌的浸润深度、TNM分期、淋巴转移、肿瘤大小等临床病理学参数有关。
Objective This study was designed to evaluate the expression of COX-2 and CCR7 in human colorectal cancer and determine their relationships and correlations with lymph node metastasis,tumor differentiation,invasion depth,lymphatic metastasis and other clinicopathologic parameters.
Methods Tissue samples of primary tumors from 80 colorectal cancer patients and normal colorectal tissue adjacent to cancer from 40 colorectal cancer patients,undergoing paraffin imbedding slices were immunohistochemically examined for COX-2 and CCR7 expressions.
Results COX-2 and CCR7 were highly expressed in colorectal cancer tissues,the positive rate of COX-2 and CCR7 in the primary tumor was 72.5%and 67.5%,respectively.A significant correlation was found between the expression scores of COX-2 and CCR7(P＜0.05),and both also were correlated with several clinicopathologic parameters, including invasion depth,lymph node metastasis,TNM stage and primary tumor size(P＜0.05),but both were not related to patients'age, sex and other factors(P＞0.05).In addition,only CCR7 expression was associated with histology and tumor site(P＜0.05).
Conclusions High expression of COX-2 and CCR7 in human colorectal cancer was a significantly correlated.COX-2 and CCR7 were significantly associated with clinicopathologic parameters,including invasion depth,lymph node metastasis,TNM stage and primary tumor size.This indicates that detection of COX-2 and CCR7 will be helpful to predicting clincally the metastasis of colorectal cancer.
引文
[1] Half EE, Arber N.Chemoprevention of colorectal cancer: two steps forward, one step back? Future Oncol, 2006, 2(6): 697-704
[2] Hawk, ET, Umar, A, Viner, JL. Colorectal cancer chemoprevention: an overview of the science. Gastroenterology, 2004, 126:1423-1447
[3] Kotake K, Honjo S, Sugihara K, et al. Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum, 2003, 46(Suppl): S32- 43
[4] Voyer, TE, Sigurdson, ER, Hanlon, AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol, 2003, 21: 2912-2919
[5] Nathanson, SD. Insights into the mechanisms of lymph node metastasis. Cancer, 2003, 98: 413-423
[6] Feng L, Wang Z. Chemopreventive effect of celecoxib in oral precancers and cancers. Laryngoscope, 2006, 116(10): 1842-1845
[7] Takaoka K, Kishimoto H, Segawa E, et al. Elevated cell migration, invasion and tumorigenicity in human KB carcinoma cells transfected with COX-2 cDNA. Int J Oncol, 2006, 29(5): 1095-1101
[8] Kanaoka S, Takai T, Yoshida K. Cyclooxygenase-2 and tumor biology. Adv Clin Chem, 2007,43:59-78
[9] Rostom A, Dube C, Lewin G, et al. Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U. S. Preventive Services Task Force. Ann Intern Med, 2007, 146(5): 376-89
[10] Higuchi T, Iwama T, Yoshinaga K, et al. A randomized, double-blind, placebo- controlled trial of the effects of Rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res, 2003, 9: 4756-4760
[11] Seno H, Oshima M, Ishikawa T, et al. Cyclooxygenase-2 and prostaglandin E2 receptor EP2-dependent angiogenesis in APCΔ716 Mouse intestinal polyps. Cancer Res, 2002, 62: 506 -511
[12] Oshima, M, Dinchuk, JE, Kargman, SL et al. Suppression of intestinal polyposis in knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell, 1996, 87: 803-809
[13] Labile Togba Soumaoro, Hiroyuki Uetake, Tetsuro Higuchi,et al. Cyclooxygenase-2 Expression: A Significant Prognostic Indicator for Patients With Colorectal Cancer. Clinical Cancer Research, 2004, 1: 8465-8471
[14] Chell S, Kadi A, Williams AC, et al. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta, 2006, 1766(1): 104-119
[15] Lev-Ari S, Maimon Y, Strier L, Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. J Soc Integr Oncol, 2006, 4(1):21-26
[16] Chell SD, Witherden IR, Dobson RR, et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence.Cancer Res, 2006, 66(6): 3106-3113
[17] Mashino K, Sadanaga N, Yamaguchi H, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res, 2002, 62:2937-2941
[18] Neslihan Cabioglu, M. Sertac Yazici, Banu Arun, et al. CCR7 and CXCR4 as Novel Biomarkers Predicting Axillary Lymph Node Metastasis in T1Breast Cancer. Clin Cancer Res 2005, 11(16): 5686-5693
[19 Schimanski CC, Schwald S, Simiantonaki N, et al. Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal Cancer. Clinical Cancer Research, 2005, 11: 1743-1750
[20] Walser TC, Fulton AM. The role of chemokines in the biology and therapy of breast cancer. Breast Dis, 2004, 20: 137-143
[21] Guo H, Tatsuguchi A, Shinji S, et al. Cyclooxygenase-2 expression correlates with membrane-type-1 matrix metalloproteinase expression in colorectal cancer tissue. Dis Colon Rectum, 2006, 49(8): 1184-92
[22] Konturek PC, Rembiasz K, Burnat G, et al. Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. Dig Dis Sci, 2006, 51(4): 779-87
[23] Elke Scandella, Ying Men, Daniel F. Legler, et al. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood, 2004, 103(5): 1595-1601
[24] Elke Scandella, Ying Men, Silke Gillessen, et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood, 2002, 100(4): 1354-1361
[25] Noelia Sanchez-Sanchez, Lorena Riol-Blanco, Gonzalo de la Rosa, et al. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood, 2004,104(3): 619-625
[26] Anggard E, Matschinsky FM, Samuelsson B, et al. Prostaglandins enzymatic analysis. Science, 1969, 163: 479-480
[27] Nugteren DH, Van Dorp DA, Bergstrom S, et al. Absolute configuration of the prostaglandins. Nature, 1966, 212: 38-39
[28] Ari Ristima¨ki, Anna Sivula, Johan Lundin, et al. Prognostic Significance of Elevated Cyclooxygenase-2 Expression in Breast Cancer. Cancer Research, 2002, 62: 632-635
[29] Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 1995, 83: 493-501
[30] Kakiuchi Y, Tsuji S, Tsujii M. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens in colon cancer cells and enhanced liver metastasis. Cancer Res, 2002, 62: 1567-1572
[31] Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA, 1997, 94: 3336-3340
[32] Fernandez PM, Manyak MJ, Patierno SR. Effect of the cyclooxygenase-2 selective inhibitor NS398 on the secretion of matrix metalloproteinases (MMP-2 and MMP-9) and tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2) from human prostate tumor cells. Proc Am Assoc Cancer Res, 2000, 41: 131-132
[33] Zlotnik A. Chemokines and cancer. Int J Cancer, 2006, 119(9): 2026-2029
[34] Elke Scandella, Ying Men, Daniel F. Legler, et al. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood, 2004, 103(5): 1595-1601
[35] Elke Scandella, Ying Men, Silke Gillessen, et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood, 2002, 100(4): 1354-1361
[36] Noelia Sanchez-Sanchez, Lorena Riol-Blanco, Gonzalo de la Rosa, et al. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood, 2004, 104(3): 619-625
[37] Hirao M, Onai N, Hiroishi K, et al. chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res, 2000, 60(8): 2209-2217
[38] Y. Nishioka et al. chemokine receptor-7 on dendritic cells is induced apoptosis after incubated with tumor cells. Cancer Res, 1999, 59: 4035-4041
[39]Muller A, Homey B, Soto H, Ge N, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001, 410(6824): 24-25
[40] Tsuzuki H, Takahashi N, Kojima A, et al. Oral and oropharyngeal squamous cell carcinomas expressing CCR7 have poor prognoses. Auris Nasus Larynx, 2006, 33(1): 37-42
[41] Mashino K, Sadanaga N, Yamaguchi H, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res, 2002, 62:2937-2941
[42] Schmausser B, Endrich S, Brandlein S, et al.The chemokine receptor CCR7 is expressed on epithelium of non-inflamed gastric mucosa, Helicobacter pylori gastritis, gastric carcinoma and its precursor lesions and up-regulated by H. pylori. Clin Exp Immunol, 2005,139 (2): 323-327
[43] Kwak MK, Hur K, Park do J, et al. Expression of chemokine receptors in human gastric cancer. Tumour Biol, 2005, 26(2): 65-70
[44] Ding Y, Shimada Y, Maeda M, et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res, 2003, 9(9): 3406-3412
[45] Heresi GA, Wang J, Taichman R, et al. Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression. Urol Oncol, 2005, 23(4): 261-267
[46] Wang J, Xi L, Gooding W, Godfrey TE, et al. Chemokine receptors 6 and 7 identify a metastatic expression pattern in squamous cell carcinoma of the head and neck. Adv Otorhinolaryngol, 2005, 62: 121-133
[47] Masai K, Iwashita Y, Tominaga M, et al. mRNA expression of chemokine receptors in hepatic and pancreatic tumor cell lines. Gan To Kagaku Ryoho, 2004, 31(8):1261-1263
[48]Lopez-Giral S,Quintana NE,Cabrerizo M,et al.Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination.J Leukoc Biol,2004,76(2):462-471
[49]Neslihan Cabioglu,M.Sertac Yazici,Banu Arun,et al.CCR7 and CXCR4as Novel Biomarkers Predicting Axillary Lymph Node Metastasis in T 1Breast Cancer.Clin Cancer Res 2005,11(16):5686-5693
[50]Andre F,Cabioglu N,Assi H,et al.Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer.Ann Oncol,2006 Apr 20;[Epub ahead of print]
[51]Wilson JL,Burchell J,Grimshaw MJ.Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1.Cancer Res,2006,66(24):11802-11807
[52]黄俊辉。原发性乳腺癌VEGF-C、CXCR4表达与肿瘤淋巴管生成及淋巴转移机制的研究:[博士学位论文中南大学].长沙:中南大学,2005
[53]Yu YY,Ji J,Zhang Y,et al.Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis.World J Gastroenterol,2004,10(6):783-790
[1] Chang YW, Marlin JW, Chance TW, Jakobi R. RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility. Cancer Res, 2006, 66(24): 11700-11708
[2] Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest, 2001, 107(12): 1491-1495
[3] Pugh S, Thomas G. Patients w ith adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut, 1994, 35(5): 675-678
[4] Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol, 2005, 23(12): 2840-2855
[5] Dempke W, Rie C, Grothey A, et al. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Clin Invest, 2001, 127(7): 411-417
[6] Rodrigues S, Bruyneel E, Rodrigue CM, et al. Cyclooxygenase 2 and carcinogenesis. Bull Cancer, 2004, 91 Suppl2: S61-76
[7] Sheng H, Shao J, Dixon DA, et al. Transforming growth factor betal enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem, 2000, 275: 6628-6635
[8] Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem, 2000, 69: 145-182
[9] Fux R, Schwab M, Thon KP, Gleiter CH, Fritz P. Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res, 2005, 11(13): 4754-4760
[10] Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, Wolfe MM. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res, 2005, 11(4): 1618-1628
[11] Kobayashi H, Uetake H, Higuchi T, Enomoto M, Sugihara K. JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats. BMC Cancer, 2005, 5: 26
[12] Pai R, Nakamura T, Moon WS, Tarnawski AS. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J, 2003, 17(12): 1640-1647
[13] Tsutsui T, Tamura Y, Yagi E, et al. Involvement of genoroxic effects in the initiation of estrogen-induced cellular transformation studies using Syrian hamster embryo cells treated with 17beta-estradiol and eight of its metabolites. Int J Cancer, 2000, 86(1): 8-14
[14] Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem, 2001, 276: 18563-18569
[15] Labile Togba Soumaoro, Hiroyuki Uetake, Tetsuro Higuchi, et al. Cyclooxygenase-2 Expression: A Significant Prognostic Indicator for Patients With Colorectal Cancer. Clinical Cancer Research, 2004, 1: 8465-8471
[16] Neufang G, Furstenberger G, Heidt M, et al. Abnormal differentiation of epidermidis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci USA, 2001, 98: 7629-7634
[17] Muller-Decker L, Neufang G, Berger I, et al. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA, 2002, 99: 12483-12488
[18] Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc (Delta716) knockout mice. Nat Med, 2001, 7: 1048-1051
[19] Takashi Kuwano, Shintaro Nakao, Hidetaka Yamamoto, et al. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. The FASEB Journal, 2004, 18(20): 300-310
[20]Kanaoka S, Takai T, Yoshida K. Cyclooxygenase-2 and tumor biology. Adv Clin Chem, 2007,43:59-78
[21] Pai R, Soreghan B, Szabo IL, et al. Prostaglandin E2 transactivates EGF receptor a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med, 2002, 8(3):289-293
[22] Shao J, Lee SB, Guo H, et al. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res, 2003, 63(17) 5218-5123
[23] Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, uBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol, 2005, 23(2): 254-266
[24] Buchanan FG, Wang D, Bargiacchi F, et al. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem, 2003, 278(37): 35451-35457
[25] Wang S, Zhang YC, Ye YJ, Cui ZR, Fang WG. Correlation between Stat3 signal transduction pathway and expression of cyclooxygenase-2 in colorectal cancer cells. Zhonghua Yi Xue Za Zhi. 2005, 85(41): 2899-2904.
[26] Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer, 2002, 2(10)727-739
[27] Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs:insight into mechanisms and im-plications for cancer growth and ulcer healing.Nat Med, 1999, 5(12): 1418-1423
[28] Mcginty A, Chang YM, Sorokin A, et al. Cyclooxygenase-2expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cells. J Biol Chem, 2000, 275: 12095-12101
[29] Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 2000, 60(5): 1306-1311
[30] Soumaoro LT, Uetake H, Takagi Y, et al. Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum, 2006, 49(3): 392-398
[31] Ishizaki T, Katsumata K, Tsuchida A, Wada T, Mori Y, Hisada M, Kawakita H, Aoki T. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Int J Mol Med, 2006, 17(2): 357-362
[32] Kakiuchi Y, Tsuji S, Tsujii M. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens in colon cancer cells and enhanced liver metastasis. Cancer Res, 2002, 62(5): 1567-1572
[33] Kim R, Emi M, Tanabe K. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responsesCancer. Biol Ther, 2005, 4(9): 924-933
[34] Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol, 2000, 164:361-70
[35] Dubois RN, Shao J, Tsujii M, et al. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res, 1999, 56(4): 733-737
[36] Yamac D, Celenkoglu G, Coskun U, et al. Prognostic importance of COX-2 expression in patients with colorectal cancer. Pathol Res Pract, 2005, 201(7): 497-502
[37] Liu ZJ, Yu JP, et al. Expressions of cyclooxygenase-2 and cholecystokinin-B receptor mRNA in human colonic cancer and their significances. Ai Zheng, 2005, 24(2): 237-240
[38] Zimmermann KC, Sarbia M, Weber AA, et al.Cyclooxygenase-2ex-pression in human esophageal carcinoma.Cancer Res, 1999, 59(1): 198-204
[39] Tucker ON, Dannenberg AJ, Yang K, et al. Cyclooxygenase-2expres-sion is up-regulated in human pancreatic cancer.Cancer Res, 1999, 59(5): 987-990
[40] Koga H, Sakisaka S? Ohishi M, et al. Expression of cyclooxygenase-2in human hepatocellular carcinoma:relevance to tumor dedifferentiation. Hepatology, 1999, 29(3): 688-696
[41] Howe LR, Dannenberg AJ. A role for cyclooxygenase-2inhibitors in the prevention and treatment of cancer. Semin Oncol, 2002, 29(3): 111-119
[42] Kobayashi H, Uetake H, Higuchi T, Enomoto M, Sugihara K. JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats. BMC Cancer, 2005, 5: 26
[43] Koga H, Sakisaka S, Ohishi M, Kawaguchi T, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 1999, 29(3): 688-696
[44] Alfred S-L Cheng, Henry L-Y Chan, Wai K Leung, et al. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Modern Pathology, 2004, 17: 1169-1179
[45] Reilly TP, Brady JN, Marchick MR, et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol, 2001, 14(12): 1620-1628
[46] Bertagnolli MM. COX-2 and cancer chemoprevention: picking up the pieces. Recent Results Cancer Res, 2007, 174: 73-78
[47] Takahashi T, Kozaki K, Yatabe Y, et al. Increased expression of COX-2 in the development of human lung cancers. J Environ Pathol Toxicol Oncol, 2002, 21(2): 177-181
[48] Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer, 2004, 4(1): 71-78
[49] Shiotani H, Denda A, Yamamoto K, et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res, 2001, 61(4): 1451-1456
[50] Holla VR, Mann JR, Shi Q, DuBois RN. Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer. J Biol Chem, 2006, 281(5): 2676-2682
[51] Zhou Y, Ran J, Tang C, et al. Effect of Celecoxib on E-cadherin, VEGF, Microvessel Density and Apoptosis in Gastric Cancer. Cancer Biol Ther, 2007, 6(2): [Epub ahead of print]
[52] Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res, 2000, 60(12): 1326-1331
[53] Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res, 2001, 7(10): 2998-3005
[54] He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell, 1999, 99: 335-345
[55] Roma AA, Prayson RA. Expression of cyclooxygenase-2 in ependymal tumors. Neuropathology, 2006, 26(5): 422-428
[56] Nystrom ML, McCulloch D, Weinreb PH, et al. Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion. Cancer Res, 2006, 66(22): 10833-10842
[1] Zlotnik, A., and Yoshie, 0. Chemokines: a new classification system and their role in immunity. Immunity, 2000, 12: 121-127
[2] Zlotnik A. Chemokines and cancer. Int J Cancer, 2006, 119(9): 2026-2029
[3] Muller A, Homey B, Soto H, Ge N, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001, 410(6824): 24-25
[4] Kakinuma T, Hwang ST.Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol, 2006, 79(4): 639-651
[5] Walser TC, Fulton AM. The role of chemokines in the biology and therapy of breast cancer. Breast Dis, 2004, 20: 137-143
[6] Dieu, M. C, Vanbervliet, B., Vicari, A., et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med., 1998, 188: 373-386
[7] Hirao, M., Onai, N., Hiroishi, K., et al. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res., 2000, 60: 2209-2217
[8] Gunn, M. D., Kyuwa, S., Tarn, C., et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med., 1999, 189: 451-460
[9] Elke Scandella, Ying Men, Daniel F. Legler, et al. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood, 2004, 103(5): 1595-1601
[10] Elke Scandella, Ying Men, Silke Gillessen, et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood, 2002, 100(4): 1354-1361
[11] Noelia Sanchez-Sanchez, Lorena Riol-Blanco, Gonzalo de la Rosa, et al. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood, 2004, 104(3): 619-625
[12] Hirao M, Onai N, Hiroishi K, et al. chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res, 2000, 60(8): 2209-2217
[13] Y. Nishioka et al. chemokine receptor-7 on dendritic cells is induced apoptosis after incubated with tumor cells. Cancer Res, 1999, 59: 4035-4041
[14] Andre F, Cabioglu N, Assi H, et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol, 2006 Apr 20, [Epub ahead of print]
[15] Neslihan Cabioglu, M. Sertac Yazici, Banu Arun, et al. CCR7 and CXCR4 as Novel Biomarkers Predicting Axillary Lymph Node Metastasis in TlBreast Cancer. Clin Cancer Res, 2005, 11(16): 5686-5693
[16] Cabioglu N, Gong Y, Islam R, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol, 2007 Mar 9; [Epub ahead of print]
[17] Henry E. Wiley, Erik B. Gonzalez,Wusi Maki, et ah Expression of CC Chemokine Receptor-7 and Regional Lymph Node Metastasis of B16 Murine Melanoma Journal of the National Cancer Institute, 2001, 93(21): 1638-1643
[18] Hiroya Takeuchi,l Akihide Fujimoto,et ah CCL21 Chemokine Regulates Chemokine Receptor CCR7 Bearing Malignant Melanoma Cells. Clinical Cancer Research, 2004, 10, 2351-2358
[19] Ding Y, Shimada Y, Maeda M, et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res, 2003, 9(9): 3406-3412
[20] Mashino K, Sadanaga N, Yamaguchi H, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res, 2002, 62: 2937-2941
[21] Schmausser B, Endrich S, Brandlein S, et al. The chemokine receptor CCR7 is expressed on epithelium of non-inflamed gastric mucosa, Helicobacter pylori gastritis, gastric carcinoma and its precursor lesions and up-regulated by H. pylori. Clin Exp Immunol, 2005, 139 (2): 323-327
[22] Yu YY, Ji J, Zhang Y, et al. Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis. World J Gastroenterol, 2004, 10 (6): 783-790
[23] Kwak MK, Hur K, Park do J, et al. Expression of chemokine receptors in human gastric cancer. Tumour Biol, 2005, 26(2): 65-70
[24] Schimanski CC, Schwald S, Simiantonaki N, et al. Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal Cancer. Clinical Cancer Research, 2005, 11: 1743-1750
[25] Gunther K, Leier J, Henning G,et al. Prediction of lymph node metastasis in colorectal carcinoma by expression of chemokine receptor CCR7. Int J Cancer, 2005, 116(5): 726-733.
[26] Till KJ, Lin K, Zuzel M, et al. The chemokine receptor CCR7 and alpha 4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood, 2002, 99(8):2977-2984.
[27] Ghobrial IM, Bone ND, Stenson MJ, et al. Expression of chemokine receptors CXCR4 and CCR7 and desease progression in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, Mayo Clin Proc, 2004, 79(3): 318-325
[28] Lopez-Giral S, Quintana NE, Cabrerizo M, et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol, 2004, 76(2): 462-471
[29]Coreione A, Arduino N, Ferretti E, et al. CCL19 and CXCL12 Trigger in vitro chemotaxis of human mantle cell lymphoma B cells, Clin Cancer Res, 2004, 10(3): 964-971
[30] Hopken UE, Foss HD, Meyer D, et al. Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood, 2002,99(4): 1109-1116.
[31] Takanami. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: Correlation with lymph node metastasis. Int J Cancer, 2003, 105(2): 186-189
[32] Tsuzuki H, Takahashi N, Kojima A, et al. Oral and oropharyngeal squamous cell carcinomas expressing CCR7 have poor prognoses. Auris Nasus Larynx, 2006, 33(1): 37-42
[33] Wang J, Xi L, Gooding W, Godfrey TE, et al. Chemokine receptors 6 and 7 identify a metastatic expression pattern in squamous cell carcinoma of the head and neck. Adv Otorhinolaryngol, 2005, 62: 121-133
[34] Masai K, Iwashita Y, Tominaga M, et al. mRNA expression of chemokine receptors in hepatic and pancreatic tumor cell lines. Gan To Kagaku Ryoho, 2004, 31(8): 1261-1263
[35] Heresi GA, Wang J, Taichman R, et al. Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression. Urol Oncol, 2005, 23(4): 261-267
[36] Schimanski CC, Bahre R, Gockel I, et al. Chemokine receptor CCR7 enhances intrahepatic and lymphatic dissemination of human hepatocellular cancer. Oncol Rep, 2006, 16(1): 109-113
[37] Kodama J, Hasengaowa, Kusumoto T, Seki N, et al. Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann Oncol, 2007, 18(1): 70-76
[38] Yu YY, Ji J, Zhang Y, et al. Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis. World J Gastroenterol, 2004, 10 (6): 783-790
[39] Wilson JL, Burchell J, Grimshaw MJ. Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. Cancer Res, 2006, 66(24): 11802-11807
[2] Hawk, ET, Umar, A, Viner, JL. Colorectal cancer chemoprevention: an overview of the science. Gastroenterology, 2004, 126:1423-1447
[3] Kotake K, Honjo S, Sugihara K, et al. Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum, 2003, 46(Suppl): S32- 43
[4] Voyer, TE, Sigurdson, ER, Hanlon, AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol, 2003, 21: 2912-2919
[5] Nathanson, SD. Insights into the mechanisms of lymph node metastasis. Cancer, 2003, 98: 413-423
[6] Feng L, Wang Z. Chemopreventive effect of celecoxib in oral precancers and cancers. Laryngoscope, 2006, 116(10): 1842-1845
[7] Takaoka K, Kishimoto H, Segawa E, et al. Elevated cell migration, invasion and tumorigenicity in human KB carcinoma cells transfected with COX-2 cDNA. Int J Oncol, 2006, 29(5): 1095-1101
[8] Kanaoka S, Takai T, Yoshida K. Cyclooxygenase-2 and tumor biology. Adv Clin Chem, 2007,43:59-78
[9] Rostom A, Dube C, Lewin G, et al. Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U. S. Preventive Services Task Force. Ann Intern Med, 2007, 146(5): 376-89
[10] Higuchi T, Iwama T, Yoshinaga K, et al. A randomized, double-blind, placebo- controlled trial of the effects of Rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res, 2003, 9: 4756-4760
[11] Seno H, Oshima M, Ishikawa T, et al. Cyclooxygenase-2 and prostaglandin E2 receptor EP2-dependent angiogenesis in APCΔ716 Mouse intestinal polyps. Cancer Res, 2002, 62: 506 -511
[12] Oshima, M, Dinchuk, JE, Kargman, SL et al. Suppression of intestinal polyposis in knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell, 1996, 87: 803-809
[13] Labile Togba Soumaoro, Hiroyuki Uetake, Tetsuro Higuchi,et al. Cyclooxygenase-2 Expression: A Significant Prognostic Indicator for Patients With Colorectal Cancer. Clinical Cancer Research, 2004, 1: 8465-8471
[14] Chell S, Kadi A, Williams AC, et al. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta, 2006, 1766(1): 104-119
[15] Lev-Ari S, Maimon Y, Strier L, Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. J Soc Integr Oncol, 2006, 4(1):21-26
[16] Chell SD, Witherden IR, Dobson RR, et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence.Cancer Res, 2006, 66(6): 3106-3113
[17] Mashino K, Sadanaga N, Yamaguchi H, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res, 2002, 62:2937-2941
[18] Neslihan Cabioglu, M. Sertac Yazici, Banu Arun, et al. CCR7 and CXCR4 as Novel Biomarkers Predicting Axillary Lymph Node Metastasis in T1Breast Cancer. Clin Cancer Res 2005, 11(16): 5686-5693
[19 Schimanski CC, Schwald S, Simiantonaki N, et al. Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal Cancer. Clinical Cancer Research, 2005, 11: 1743-1750
[20] Walser TC, Fulton AM. The role of chemokines in the biology and therapy of breast cancer. Breast Dis, 2004, 20: 137-143
[21] Guo H, Tatsuguchi A, Shinji S, et al. Cyclooxygenase-2 expression correlates with membrane-type-1 matrix metalloproteinase expression in colorectal cancer tissue. Dis Colon Rectum, 2006, 49(8): 1184-92
[22] Konturek PC, Rembiasz K, Burnat G, et al. Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. Dig Dis Sci, 2006, 51(4): 779-87
[23] Elke Scandella, Ying Men, Daniel F. Legler, et al. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood, 2004, 103(5): 1595-1601
[24] Elke Scandella, Ying Men, Silke Gillessen, et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood, 2002, 100(4): 1354-1361
[25] Noelia Sanchez-Sanchez, Lorena Riol-Blanco, Gonzalo de la Rosa, et al. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood, 2004,104(3): 619-625
[26] Anggard E, Matschinsky FM, Samuelsson B, et al. Prostaglandins enzymatic analysis. Science, 1969, 163: 479-480
[27] Nugteren DH, Van Dorp DA, Bergstrom S, et al. Absolute configuration of the prostaglandins. Nature, 1966, 212: 38-39
[28] Ari Ristima¨ki, Anna Sivula, Johan Lundin, et al. Prognostic Significance of Elevated Cyclooxygenase-2 Expression in Breast Cancer. Cancer Research, 2002, 62: 632-635
[29] Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 1995, 83: 493-501
[30] Kakiuchi Y, Tsuji S, Tsujii M. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens in colon cancer cells and enhanced liver metastasis. Cancer Res, 2002, 62: 1567-1572
[31] Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA, 1997, 94: 3336-3340
[32] Fernandez PM, Manyak MJ, Patierno SR. Effect of the cyclooxygenase-2 selective inhibitor NS398 on the secretion of matrix metalloproteinases (MMP-2 and MMP-9) and tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2) from human prostate tumor cells. Proc Am Assoc Cancer Res, 2000, 41: 131-132
[33] Zlotnik A. Chemokines and cancer. Int J Cancer, 2006, 119(9): 2026-2029
[34] Elke Scandella, Ying Men, Daniel F. Legler, et al. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood, 2004, 103(5): 1595-1601
[35] Elke Scandella, Ying Men, Silke Gillessen, et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood, 2002, 100(4): 1354-1361
[36] Noelia Sanchez-Sanchez, Lorena Riol-Blanco, Gonzalo de la Rosa, et al. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood, 2004, 104(3): 619-625
[37] Hirao M, Onai N, Hiroishi K, et al. chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res, 2000, 60(8): 2209-2217
[38] Y. Nishioka et al. chemokine receptor-7 on dendritic cells is induced apoptosis after incubated with tumor cells. Cancer Res, 1999, 59: 4035-4041
[39]Muller A, Homey B, Soto H, Ge N, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001, 410(6824): 24-25
[40] Tsuzuki H, Takahashi N, Kojima A, et al. Oral and oropharyngeal squamous cell carcinomas expressing CCR7 have poor prognoses. Auris Nasus Larynx, 2006, 33(1): 37-42
[41] Mashino K, Sadanaga N, Yamaguchi H, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res, 2002, 62:2937-2941
[42] Schmausser B, Endrich S, Brandlein S, et al.The chemokine receptor CCR7 is expressed on epithelium of non-inflamed gastric mucosa, Helicobacter pylori gastritis, gastric carcinoma and its precursor lesions and up-regulated by H. pylori. Clin Exp Immunol, 2005,139 (2): 323-327
[43] Kwak MK, Hur K, Park do J, et al. Expression of chemokine receptors in human gastric cancer. Tumour Biol, 2005, 26(2): 65-70
[44] Ding Y, Shimada Y, Maeda M, et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res, 2003, 9(9): 3406-3412
[45] Heresi GA, Wang J, Taichman R, et al. Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression. Urol Oncol, 2005, 23(4): 261-267
[46] Wang J, Xi L, Gooding W, Godfrey TE, et al. Chemokine receptors 6 and 7 identify a metastatic expression pattern in squamous cell carcinoma of the head and neck. Adv Otorhinolaryngol, 2005, 62: 121-133
[47] Masai K, Iwashita Y, Tominaga M, et al. mRNA expression of chemokine receptors in hepatic and pancreatic tumor cell lines. Gan To Kagaku Ryoho, 2004, 31(8):1261-1263
[48]Lopez-Giral S,Quintana NE,Cabrerizo M,et al.Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination.J Leukoc Biol,2004,76(2):462-471
[49]Neslihan Cabioglu,M.Sertac Yazici,Banu Arun,et al.CCR7 and CXCR4as Novel Biomarkers Predicting Axillary Lymph Node Metastasis in T 1Breast Cancer.Clin Cancer Res 2005,11(16):5686-5693
[50]Andre F,Cabioglu N,Assi H,et al.Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer.Ann Oncol,2006 Apr 20;[Epub ahead of print]
[51]Wilson JL,Burchell J,Grimshaw MJ.Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1.Cancer Res,2006,66(24):11802-11807
[52]黄俊辉。原发性乳腺癌VEGF-C、CXCR4表达与肿瘤淋巴管生成及淋巴转移机制的研究:[博士学位论文中南大学].长沙:中南大学,2005
[53]Yu YY,Ji J,Zhang Y,et al.Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis.World J Gastroenterol,2004,10(6):783-790
[1] Chang YW, Marlin JW, Chance TW, Jakobi R. RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility. Cancer Res, 2006, 66(24): 11700-11708
[2] Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest, 2001, 107(12): 1491-1495
[3] Pugh S, Thomas G. Patients w ith adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut, 1994, 35(5): 675-678
[4] Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol, 2005, 23(12): 2840-2855
[5] Dempke W, Rie C, Grothey A, et al. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Clin Invest, 2001, 127(7): 411-417
[6] Rodrigues S, Bruyneel E, Rodrigue CM, et al. Cyclooxygenase 2 and carcinogenesis. Bull Cancer, 2004, 91 Suppl2: S61-76
[7] Sheng H, Shao J, Dixon DA, et al. Transforming growth factor betal enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem, 2000, 275: 6628-6635
[8] Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem, 2000, 69: 145-182
[9] Fux R, Schwab M, Thon KP, Gleiter CH, Fritz P. Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res, 2005, 11(13): 4754-4760
[10] Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, Wolfe MM. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res, 2005, 11(4): 1618-1628
[11] Kobayashi H, Uetake H, Higuchi T, Enomoto M, Sugihara K. JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats. BMC Cancer, 2005, 5: 26
[12] Pai R, Nakamura T, Moon WS, Tarnawski AS. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J, 2003, 17(12): 1640-1647
[13] Tsutsui T, Tamura Y, Yagi E, et al. Involvement of genoroxic effects in the initiation of estrogen-induced cellular transformation studies using Syrian hamster embryo cells treated with 17beta-estradiol and eight of its metabolites. Int J Cancer, 2000, 86(1): 8-14
[14] Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem, 2001, 276: 18563-18569
[15] Labile Togba Soumaoro, Hiroyuki Uetake, Tetsuro Higuchi, et al. Cyclooxygenase-2 Expression: A Significant Prognostic Indicator for Patients With Colorectal Cancer. Clinical Cancer Research, 2004, 1: 8465-8471
[16] Neufang G, Furstenberger G, Heidt M, et al. Abnormal differentiation of epidermidis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci USA, 2001, 98: 7629-7634
[17] Muller-Decker L, Neufang G, Berger I, et al. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA, 2002, 99: 12483-12488
[18] Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc (Delta716) knockout mice. Nat Med, 2001, 7: 1048-1051
[19] Takashi Kuwano, Shintaro Nakao, Hidetaka Yamamoto, et al. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. The FASEB Journal, 2004, 18(20): 300-310
[20]Kanaoka S, Takai T, Yoshida K. Cyclooxygenase-2 and tumor biology. Adv Clin Chem, 2007,43:59-78
[21] Pai R, Soreghan B, Szabo IL, et al. Prostaglandin E2 transactivates EGF receptor a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med, 2002, 8(3):289-293
[22] Shao J, Lee SB, Guo H, et al. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res, 2003, 63(17) 5218-5123
[23] Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, uBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol, 2005, 23(2): 254-266
[24] Buchanan FG, Wang D, Bargiacchi F, et al. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem, 2003, 278(37): 35451-35457
[25] Wang S, Zhang YC, Ye YJ, Cui ZR, Fang WG. Correlation between Stat3 signal transduction pathway and expression of cyclooxygenase-2 in colorectal cancer cells. Zhonghua Yi Xue Za Zhi. 2005, 85(41): 2899-2904.
[26] Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer, 2002, 2(10)727-739
[27] Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs:insight into mechanisms and im-plications for cancer growth and ulcer healing.Nat Med, 1999, 5(12): 1418-1423
[28] Mcginty A, Chang YM, Sorokin A, et al. Cyclooxygenase-2expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cells. J Biol Chem, 2000, 275: 12095-12101
[29] Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 2000, 60(5): 1306-1311
[30] Soumaoro LT, Uetake H, Takagi Y, et al. Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum, 2006, 49(3): 392-398
[31] Ishizaki T, Katsumata K, Tsuchida A, Wada T, Mori Y, Hisada M, Kawakita H, Aoki T. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Int J Mol Med, 2006, 17(2): 357-362
[32] Kakiuchi Y, Tsuji S, Tsujii M. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens in colon cancer cells and enhanced liver metastasis. Cancer Res, 2002, 62(5): 1567-1572
[33] Kim R, Emi M, Tanabe K. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responsesCancer. Biol Ther, 2005, 4(9): 924-933
[34] Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol, 2000, 164:361-70
[35] Dubois RN, Shao J, Tsujii M, et al. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res, 1999, 56(4): 733-737
[36] Yamac D, Celenkoglu G, Coskun U, et al. Prognostic importance of COX-2 expression in patients with colorectal cancer. Pathol Res Pract, 2005, 201(7): 497-502
[37] Liu ZJ, Yu JP, et al. Expressions of cyclooxygenase-2 and cholecystokinin-B receptor mRNA in human colonic cancer and their significances. Ai Zheng, 2005, 24(2): 237-240
[38] Zimmermann KC, Sarbia M, Weber AA, et al.Cyclooxygenase-2ex-pression in human esophageal carcinoma.Cancer Res, 1999, 59(1): 198-204
[39] Tucker ON, Dannenberg AJ, Yang K, et al. Cyclooxygenase-2expres-sion is up-regulated in human pancreatic cancer.Cancer Res, 1999, 59(5): 987-990
[40] Koga H, Sakisaka S? Ohishi M, et al. Expression of cyclooxygenase-2in human hepatocellular carcinoma:relevance to tumor dedifferentiation. Hepatology, 1999, 29(3): 688-696
[41] Howe LR, Dannenberg AJ. A role for cyclooxygenase-2inhibitors in the prevention and treatment of cancer. Semin Oncol, 2002, 29(3): 111-119
[42] Kobayashi H, Uetake H, Higuchi T, Enomoto M, Sugihara K. JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats. BMC Cancer, 2005, 5: 26
[43] Koga H, Sakisaka S, Ohishi M, Kawaguchi T, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 1999, 29(3): 688-696
[44] Alfred S-L Cheng, Henry L-Y Chan, Wai K Leung, et al. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Modern Pathology, 2004, 17: 1169-1179
[45] Reilly TP, Brady JN, Marchick MR, et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol, 2001, 14(12): 1620-1628
[46] Bertagnolli MM. COX-2 and cancer chemoprevention: picking up the pieces. Recent Results Cancer Res, 2007, 174: 73-78
[47] Takahashi T, Kozaki K, Yatabe Y, et al. Increased expression of COX-2 in the development of human lung cancers. J Environ Pathol Toxicol Oncol, 2002, 21(2): 177-181
[48] Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer, 2004, 4(1): 71-78
[49] Shiotani H, Denda A, Yamamoto K, et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res, 2001, 61(4): 1451-1456
[50] Holla VR, Mann JR, Shi Q, DuBois RN. Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer. J Biol Chem, 2006, 281(5): 2676-2682
[51] Zhou Y, Ran J, Tang C, et al. Effect of Celecoxib on E-cadherin, VEGF, Microvessel Density and Apoptosis in Gastric Cancer. Cancer Biol Ther, 2007, 6(2): [Epub ahead of print]
[52] Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res, 2000, 60(12): 1326-1331
[53] Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res, 2001, 7(10): 2998-3005
[54] He TC, Chan TA, Vogelstein B, et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell, 1999, 99: 335-345
[55] Roma AA, Prayson RA. Expression of cyclooxygenase-2 in ependymal tumors. Neuropathology, 2006, 26(5): 422-428
[56] Nystrom ML, McCulloch D, Weinreb PH, et al. Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion. Cancer Res, 2006, 66(22): 10833-10842
[1] Zlotnik, A., and Yoshie, 0. Chemokines: a new classification system and their role in immunity. Immunity, 2000, 12: 121-127
[2] Zlotnik A. Chemokines and cancer. Int J Cancer, 2006, 119(9): 2026-2029
[3] Muller A, Homey B, Soto H, Ge N, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001, 410(6824): 24-25
[4] Kakinuma T, Hwang ST.Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol, 2006, 79(4): 639-651
[5] Walser TC, Fulton AM. The role of chemokines in the biology and therapy of breast cancer. Breast Dis, 2004, 20: 137-143
[6] Dieu, M. C, Vanbervliet, B., Vicari, A., et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med., 1998, 188: 373-386
[7] Hirao, M., Onai, N., Hiroishi, K., et al. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res., 2000, 60: 2209-2217
[8] Gunn, M. D., Kyuwa, S., Tarn, C., et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med., 1999, 189: 451-460
[9] Elke Scandella, Ying Men, Daniel F. Legler, et al. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood, 2004, 103(5): 1595-1601
[10] Elke Scandella, Ying Men, Silke Gillessen, et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood, 2002, 100(4): 1354-1361
[11] Noelia Sanchez-Sanchez, Lorena Riol-Blanco, Gonzalo de la Rosa, et al. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood, 2004, 104(3): 619-625
[12] Hirao M, Onai N, Hiroishi K, et al. chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res, 2000, 60(8): 2209-2217
[13] Y. Nishioka et al. chemokine receptor-7 on dendritic cells is induced apoptosis after incubated with tumor cells. Cancer Res, 1999, 59: 4035-4041
[14] Andre F, Cabioglu N, Assi H, et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol, 2006 Apr 20, [Epub ahead of print]
[15] Neslihan Cabioglu, M. Sertac Yazici, Banu Arun, et al. CCR7 and CXCR4 as Novel Biomarkers Predicting Axillary Lymph Node Metastasis in TlBreast Cancer. Clin Cancer Res, 2005, 11(16): 5686-5693
[16] Cabioglu N, Gong Y, Islam R, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol, 2007 Mar 9; [Epub ahead of print]
[17] Henry E. Wiley, Erik B. Gonzalez,Wusi Maki, et ah Expression of CC Chemokine Receptor-7 and Regional Lymph Node Metastasis of B16 Murine Melanoma Journal of the National Cancer Institute, 2001, 93(21): 1638-1643
[18] Hiroya Takeuchi,l Akihide Fujimoto,et ah CCL21 Chemokine Regulates Chemokine Receptor CCR7 Bearing Malignant Melanoma Cells. Clinical Cancer Research, 2004, 10, 2351-2358
[19] Ding Y, Shimada Y, Maeda M, et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res, 2003, 9(9): 3406-3412
[20] Mashino K, Sadanaga N, Yamaguchi H, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res, 2002, 62: 2937-2941
[21] Schmausser B, Endrich S, Brandlein S, et al. The chemokine receptor CCR7 is expressed on epithelium of non-inflamed gastric mucosa, Helicobacter pylori gastritis, gastric carcinoma and its precursor lesions and up-regulated by H. pylori. Clin Exp Immunol, 2005, 139 (2): 323-327
[22] Yu YY, Ji J, Zhang Y, et al. Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis. World J Gastroenterol, 2004, 10 (6): 783-790
[23] Kwak MK, Hur K, Park do J, et al. Expression of chemokine receptors in human gastric cancer. Tumour Biol, 2005, 26(2): 65-70
[24] Schimanski CC, Schwald S, Simiantonaki N, et al. Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal Cancer. Clinical Cancer Research, 2005, 11: 1743-1750
[25] Gunther K, Leier J, Henning G,et al. Prediction of lymph node metastasis in colorectal carcinoma by expression of chemokine receptor CCR7. Int J Cancer, 2005, 116(5): 726-733.
[26] Till KJ, Lin K, Zuzel M, et al. The chemokine receptor CCR7 and alpha 4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood, 2002, 99(8):2977-2984.
[27] Ghobrial IM, Bone ND, Stenson MJ, et al. Expression of chemokine receptors CXCR4 and CCR7 and desease progression in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, Mayo Clin Proc, 2004, 79(3): 318-325
[28] Lopez-Giral S, Quintana NE, Cabrerizo M, et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol, 2004, 76(2): 462-471
[29]Coreione A, Arduino N, Ferretti E, et al. CCL19 and CXCL12 Trigger in vitro chemotaxis of human mantle cell lymphoma B cells, Clin Cancer Res, 2004, 10(3): 964-971
[30] Hopken UE, Foss HD, Meyer D, et al. Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood, 2002,99(4): 1109-1116.
[31] Takanami. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: Correlation with lymph node metastasis. Int J Cancer, 2003, 105(2): 186-189
[32] Tsuzuki H, Takahashi N, Kojima A, et al. Oral and oropharyngeal squamous cell carcinomas expressing CCR7 have poor prognoses. Auris Nasus Larynx, 2006, 33(1): 37-42
[33] Wang J, Xi L, Gooding W, Godfrey TE, et al. Chemokine receptors 6 and 7 identify a metastatic expression pattern in squamous cell carcinoma of the head and neck. Adv Otorhinolaryngol, 2005, 62: 121-133
[34] Masai K, Iwashita Y, Tominaga M, et al. mRNA expression of chemokine receptors in hepatic and pancreatic tumor cell lines. Gan To Kagaku Ryoho, 2004, 31(8): 1261-1263
[35] Heresi GA, Wang J, Taichman R, et al. Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression. Urol Oncol, 2005, 23(4): 261-267
[36] Schimanski CC, Bahre R, Gockel I, et al. Chemokine receptor CCR7 enhances intrahepatic and lymphatic dissemination of human hepatocellular cancer. Oncol Rep, 2006, 16(1): 109-113
[37] Kodama J, Hasengaowa, Kusumoto T, Seki N, et al. Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann Oncol, 2007, 18(1): 70-76
[38] Yu YY, Ji J, Zhang Y, et al. Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis. World J Gastroenterol, 2004, 10 (6): 783-790
[39] Wilson JL, Burchell J, Grimshaw MJ. Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. Cancer Res, 2006, 66(24): 11802-11807
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |